Metabolic imaging by hyperpolarized 13C magnetic resonance imaging for in vivo tumor diagnosis.

The "Warburg effect," an elevation in aerobic glycolysis, may be a fundamental property of cancer cells. For cancer diagnosis and treatment, it would be valuable if elevated glycolytic metabolism could be quantified in an image in animals and humans. The pyruvate molecule is at the metabolic crossroad for energy delivery inside the cell, and with a noninvasive measurement of the relative transformation of pyruvate into lactate and alanine within a biologically relevant time frame (seconds), it may be possible to quantify the glycolytic status of the cells. We have examined the metabolism after i.v. injection of hyperpolarized (13)C-pyruvate in rats with implanted P22 tumors. The strongly enhanced nuclear magnetic resonance signal generated by the hyperpolarization techniques allows mapping of pyruvate, lactate, and alanine in a 5 x 5 x 10 mm(3) imaging voxel using a 1.5 T magnetic resonance scanner. The magnetic resonance scanning (chemical shift imaging) was initiated 24 seconds after the pyruvate injection and had a duration of 14 seconds. All implanted tumors showed significantly higher lactate content than the normal tissue. The results indicate that noninvasive quantification of localized Warburg effect may be possible.

[1]  M. Thaning,et al.  Real-time metabolic imaging. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[2]  M. Neeman,et al.  Magnetic resonance imaging visualization of hyaluronidase in ovarian carcinoma. , 2005, Cancer research.

[3]  Abass Alavi,et al.  Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  Peng Huang,et al.  Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. , 2005, Cancer research.

[5]  A. Harris,et al.  Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumor-associated stroma. , 2005, Neoplasia.

[6]  K. Garber.  Energy boost: the Warburg effect returns in a new theory of cancer. , 2004, Journal of the National Cancer Institute.

[7]  T. Tsukiyama,et al.  Preferential accumulation of 11C in human brain tumors after intravenous injection of 11C-1-pyruvate , 2004, European Journal of Nuclear Medicine.

[8]  Arend Heerschap,et al.  A chemometric approach for brain tumor classification using magnetic resonance imaging and spectroscopy. , 2003, Analytical chemistry.

[9]  J. Ardenkjær-Larsen,et al.  Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Jan H. Ardenkjær-Larsen,et al.  Molecular imaging with endogenous substances , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[11]  V. L. Doyle,et al.  Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy , 2003, Magnetic resonance in medicine.

[12]  A. Padhani.  MRI for assessing antivascular cancer treatments. , 2003, The British journal of radiology.

[13]  M. Stratford,et al.  The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. , 2002, International journal of oncology.

[14]  B. Vojnovic,et al.  Evaluation of the anti‐vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI , 2002, NMR in biomedicine.

[15]  S. Huffel,et al.  MR spectroscopy quantitation: a review of time‐domain methods , 2001, NMR in biomedicine.

[16]  H. Huisman,et al.  Accurate estimation of pharmacokinetic contrast‐enhanced dynamic MRI parameters of the prostate , 2001, Journal of magnetic resonance imaging : JMRI.

[17]  David O. Cosgrove,et al.  Textbook of Contrast Media , 1999 .

[18]  G. Tozer,et al.  Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. , 1997, Cancer research.

[19]  G. Tozer,et al.  Modification of tumour blood flow using the hypertensive agent, angiotensin II. , 1993, British Journal of Cancer.

[20]  B. Ross,et al.  The biochemistry of living tissues: Examination by MRS , 1992, NMR in biomedicine.

[21]  W. Negendank,et al.  Studies of human tumors by MRS: A review , 1992, NMR in biomedicine.

[22]  E. Newsholme,et al.  Application of metabolic-control logic to fuel utilization and its significance in tumor cells. , 1991, Advances in enzyme regulation.

[23]  E. Newsholme,et al.  Maximum activities of key enzymes of glycolysis, glutaminolysis, pentose phosphate pathway and tricarboxylic acid cycle in normal, neoplastic and suppressed cells. , 1990, The Biochemical journal.

[24]  S. Sharma,et al.  Activities of glycolytic enzymes in rapidly proliferating and differentiated C6 glioma cells. , 1989, Experimental cell biology.

[25]  W. Staib,et al.  Evidence for the compartmentation of pyruvate metabolism in perfused rat skeletal muscle. , 1983, The Biochemical journal.

[26]  W. Staib,et al.  Estimation of pyruvate decarboxylation in perfused rat skeletal muscle. , 1983, Biochemical and biophysical research communications.

[27]  K. Zaner,et al.  Human tumors detected by nuclear magnetic resonance. , 1974, Proceedings of the National Academy of Sciences of the United States of America.